Efficacy of Enhanced Cytokine-Induced Killer Cells as an Adjuvant Immunotherapy for Renal Cell Carcinoma: Preclinical and Clinical Studies
Table 1
The demographics and clinical characteristics of patients in the CIK group.
Age/sex
TNM
Location of metastases
CIK cycles
Disease state after CIK cell treatment
Disease state by the end of follow-up
PFS (month)
OS (month)
Case 1
54/M
T1N0M0
5
CR
CR
60
60
Case 2
28/M
T2N0M0
4
CR
CR
60
60
Case 3
80/F
T1N0M0
4
CR
CR
21
34
Case 4
73/F
T1N1M0
Renal hilar lymph node
4
PR
SD
22
35
Case 5
48/F
T2N1M0
Renal hilar lymph node
5
PR
SD
36
60
Case 6
59/M
T2N0M0
5
PR
PD
10
16
Case 7
59/M
T2N0M0
3
CR
CR
32
32
Case 8
46/M
T1N0M1
Lung
4
PR
SD
36
60
Case 9
49/F
T2N0M0
2
CR
SD
21
45
Case 10
72/M
T2N0M1
Lung
4
PR
PD
11
30
Case 11
74/M
T2N0M0
5
CR
CR
38
60
CIK cycles: each cycle included 3 CIK infusions in 1 week and followed by a three-week rest. CR: complete response; PR: partial responses; SD: stable disease; PD: progressive disease.
